News tagged with doxorubicin
Overcoming cancer drug resistance with nanoparticles
One of the ways in which cancer cells evade anticancer therapy is by producing a protein that pumps drugs out of the cell before these compounds can exert their cell-killing effects. A research team at Northwestern University ...
Nanotechnology / Bio & Medicine
Jan 20, 2012 |
5 / 5 (2) |
0
|
Breast cancer and heart disease may have common roots
Women who are at risk for breast cancer may also be at greater risk for heart disease, new research has found.
Dec 20, 2011 |
not rated yet |
0
|
More intensive chemotherapy dramatically improves recurrence, survival in younger patients with aggressive lymphoma
Younger patients with diffuse large B-cell lymphoma given a more intensive regimen of chemotherapy combined with rituximab survive significantly longer, and are approximately twice as likely to remain in remission 3 years ...
Nov 24, 2011 |
not rated yet |
0
Inhaled nanoparticles deliver potent anticancer cocktail to lung tumors and block resistance
(PhysOrg.com) -- An ideal treatment for lung cancer would be one that could be inhaled deep into lung tissue where it would deliver tumor-killing agents that would then largely stay in the lungs, avoiding the toxicities that ...
Nanotechnology / Bio & Medicine
Nov 21, 2011 |
4.8 / 5 (4) |
0
|
Through-the-nipple breast cancer therapy shows promise in early tests
Delivering anticancer drugs into breast ducts via the nipple is highly effective in animal models of early breast cancer, and has no major side effects in human patients, according to a report by Johns Hopkins Kimmel Cancer ...
Oct 26, 2011 |
5 / 5 (2) |
0
|
'Micro'-chemo and cancer pill combo tested in liver cancer patients
A combination of an oral drug, called sorafenib, and a method for injecting microbeads of chemotherapy directly into tumors has been proven safe for liver cancer patients and may improve outcomes for those who have these ...
Sep 30, 2011 |
5 / 5 (3) |
0
|
Less-toxic chemo improves outlook for advanced bladder cancer
(Medical Xpress) -- New data from the University of Rochester Medical Center confirms that an easier, two-drug chemotherapy regimen given to bladder cancer patients prior to surgery shrinks locally advanced tumors and completely ...
Aug 19, 2011 |
not rated yet |
0
Hormone reduces risk of heart failure from chemotherapy
Recent studies have shown that the heart contains cardiac stem cells that can contribute to regeneration and healing during disease and aging. However, little is known about the molecules and pathways that regulate these ...
Aug 04, 2011 |
not rated yet |
0
Dietary inorganic nitrate may reduce heart dysfunction caused by powerful anti-cancer drug
Virginia Commonwealth University researchers have found that nutrient supplementation, like the kind that is found in leafy greens, spinach and lettuce, may reduce the damage to the heart caused by a powerful anti-cancer ...
Medicine & Health / Cardiology
May 19, 2011 |
5 / 5 (1) |
0
Therapeutic nanoparticles targeted to radiation treated tumors
Radiation and chemotherapy are common partners in anticancer therapy for solid tumors, but too often, the combined side effects associated with each mode of therapy can limit how aggressively oncologists can treat their patients. ...
Nanotechnology / Bio & Medicine
Mar 28, 2011 |
not rated yet |
0
|
Nanodiamonds take big step toward battling cancer
Chemotherapy drug resistance contributes to treatment failure in more than 90 percent of metastatic cancers. Overcoming this hurdle would significantly improve cancer survival rates.
Nanotechnology / Bio & Medicine
Mar 09, 2011 |
5 / 5 (3) |
0
|
Nanoparticles deliver one-two therapeutic punch to kill tumor cells
The standard approach to cancer therapy today is to mix and match chemotherapy drugs in order to attack tumors in multiple ways. Now, two separate teams of investigators have demonstrated that using nanoparticles to deliver ...
Nanotechnology / Bio & Medicine
Dec 17, 2010 |
4.9 / 5 (7) |
1
|
Cancer scientists believe nanoparticles could accurately target tumors, avoiding side effects
In the past 40 years, scientists have learned a great deal about how cells become cancerous. Some of that knowledge has translated to new treatments, but most of the time doctors are forced to rely on standard ch ...
Nanotechnology / Bio & Medicine
Nov 18, 2010 |
5 / 5 (3) |
1
|
Combination therapy improves survival time for patients with advanced liver cancer
Treatment of inoperable advanced liver cancer with the agent doxorubicin (routinely used to treat this condition) in addition to the agent sorafenib resulted in greater overall survival and progression-free survival, compared ...
Nov 16, 2010 |
not rated yet |
0
New treatment approach to rare cancer results in prolonged survival
Aggressive treatment of anaplastic thyroid carcinoma has dramatically increased survival in the small group of patients who chose to undergo it, say physicians at Mayo Clinic. Their findings will be presented at the annual ...
May 26, 2010 |
5 / 5 (1) |
0
Doxorubicin
Doxorubicin INN ( /ˌdɒksəˈruːbəsɪn/; trade name Adriamycin; also known as hydroxydaunorubicin) is a drug used in cancer chemotherapy. It is an anthracycline antibiotic, closely related to the natural product daunomycin, and like all anthracyclines, it works by intercalating DNA.
Doxorubicin is commonly used in the treatment of a wide range of cancers, including hematological malignancies, many types of carcinoma, and soft tissue sarcomas.
Doxorubicin's most serious adverse effect is life-threatening heart damage.
The drug is administered intravenously, in the form of hydrochloride salt. It may be sold under the brand names Adriamycin PFS, Adriamycin RDF, or Rubex. Doxorubicin is photosensitive, and containers are often covered by an aluminum bag and/or brown wax paper to prevent light from affecting it.
The molecule was originally isolated in the 1950s from bacteria found in soil samples taken from Castel del Monte, an Italian castle.
For more information about Doxorubicin, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
